Novo valuation surpasses Tesla on experimental obesity drug data

Novo Nordisk (NOVOb.CO) on Thursday surpassed Tesla Inc (TSLA.O), opens new tab in market valuation after the maker of the popular weight-loss drug Wegovy announced positive early trial data for a highly anticipated new obesity drug.